Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8744812 | Clinical Microbiology and Infection | 2018 | 11 Pages |
Abstract
Metronidazole is mentioned in the ESCMID guideline as first-line therapy, but we propose that oral vancomycin will become the first choice when antibiotic treatment for CDI is necessary. Fidaxomicin is a good alternative, especially in patients at risk of relapse. Vancomycin combined with faecal microbiota transplantation remains the primary therapy for multiple recurrent CDI. We anticipate that new medication that protects the gut microbiota will be further developed and tested to prevent CDI during antibiotic therapy.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
R.E. Ooijevaar, Y.H. van Beurden, E.M. Terveer, A. Goorhuis, M.P. Bauer, J.J. Keller, C.J.J. Mulder, E.J. Kuijper,